



Form PTO - 1449 (Modified)

DATE: October 29, 2003

SHEET 1 of 1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.	SERIAL NO.
		6741.US.01	09/975,853
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT(S) Michael J. Amdahl	
(Use several sheets if necessary)		FILING DATE October 12, 2001	GROUP 1631
(37 CFR 1.98 (b))			

U.S. PATENT DOCUMENTS

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

MM	C1	K. J. Martin et al, "Therapy of Secondary Hyperparathyroidism with 19-Nor-1 α , 25-Dihydroxyvitamin D ₂ ", American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, vol. 32, no. 2, Suppl 2, October 1998, pp. S61-S66.
MM	C2	D. J. Cada et al, "Paricalcitol Injection and Ribavirin/Interferon Alfa-2b", Hospital Pharmacy, vol. 34, no. 3, 1999, pp. 303-338.
MM	C3	F. Llach et al, "The Importance of Dosing Intravenous Calcitriol in Dialysis Patients with Severe Hyperthyroidism", American Journal of Kidney Diseases: The Official Journal of National Kidney Foundation, vol. 26, no. 5, November 1995, pp. 845-851
MM	C4	S. M. Sprague et al, "Safety and Efficacy of Long-Term Treatment of Secondary Hyperparathyroidism by Low-Dose Intravenous Calcitriol", American Journal of Kidney Diseases: The Official Journal of National Kidney Foundation, vol. 19, no. 6, June 1992, pp. 532-539
MM	C5	K. J. Martin et al, "Paricalcitol Dosing According to Body Weight or Severity of Hyperparathyroidism: a Double-Blind, Multicenter, Randomized Study", American Journal of Kidney Diseases: The Official Journal of National Kidney Foundation, vol. 38, no. 5, Suppl 5, November 2001, pp. S57-S63

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)